Not bad. Most of the cash result has come from the increase in payables, but continued revenue/receipts growth and another quarter where future revenue signed exceeded current quarter revenue.
This one is still on track, it's another half year away though. Share price may be starting to get a little toppy at current levels, but the market is also starting to show confidence in management with the continual increases in future revenues and is willing to look forward and price on those expectations.
- Forums
- ASX - By Stock
- Ann: Appendix 4C - quarterly
CGS
cogstate ltd
Add to My Watchlist
0.61%
!
$1.66

Not bad. Most of the cash result has come from the increase in...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.66 |
Change
0.010(0.61%) |
Mkt cap ! $280.4M |
Open | High | Low | Value | Volume |
$1.65 | $1.68 | $1.62 | $34.96K | 21.09K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 621 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.68 | 2298 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 621 | 1.610 |
7 | 7699 | 1.600 |
1 | 3785 | 1.585 |
3 | 10722 | 1.575 |
1 | 829 | 1.570 |
Price($) | Vol. | No. |
---|---|---|
1.680 | 2298 | 1 |
1.710 | 10000 | 1 |
1.740 | 1000 | 1 |
1.750 | 1758 | 1 |
1.790 | 1789 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online